Key facts
- JHM Biopharma’s last known valuation is $159.7M (May 2024).
- It has raised $84.8M; the latest was Early Stage VC in May 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, SDIC Unity Capital, Shanghai Guofang Private Equity Fund Management Company, 3E Bioventures Capital, China Capital Zhongcai Fund Management — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for JHM Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for JHM Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About JHM Biopharma
Provider and developer of biological proteins used as medications. The company is committed to advancing the application of innovative recombinant protein drugs in endocrinology, neurotherapeutics, skin anti-aging and new-generation biomedical materials, providing breakthrough biomedical products and therapeutic solutions for patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- jhm-biopharma.com/
- Ownership
- Privately Held (backing)
JHM Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in JHM Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on JHM Biopharma in its N-PORT filings yet. We sweep new filings monthly.